Foresite Capital Management V, LLC
13F Reported Value
ⓘ$271.0M
Holdings
9
Latest Filing
2026-03-31
Filing Quarter
Q1 2026
Portfolio Overview
Foresite Capital Management V, LLC disclosed 9 positions worth $271.0M in its Form 13F-HR for Q1 2026, led by $ALMS (ALUMIS INC.) at 47.9% of the equity portfolio, followed by $CGON and $IRON. During the quarter the fund opened 3 new positions and exited 1 — including a new stake in $EIKN and a full exit from $NTRA. The portfolio is most concentrated in Healthcare (100.0% of disclosed assets). All figures are sourced directly from Foresite Capital Management V, LLC’s Form 13F-HR filing with the SEC under CIK 1792206.
AI Fund Analysis
StableSector Allocation
AUM History
Top Equity Holdings by Value
Quarterly Activity — Q1 2026
Click any card to unlockTop Holdings
- 9.2#2,817
Quality
$129.9M5,896,995 sh - 28.0#2,455
Quality
$68.0M1,004,050 sh - —
Quality
$23.9M374,069 sh - 50.9
Quality
$15.3M738,151 sh - —
Quality
$14.0M1,318,983 sh - 3.6
Quality
$9.6M477,078 sh - —
Quality
$5.5M194,125 sh - 13.2
Quality
$4.1M265,000 sh - 19.7
Quality
$773.3K25,905 sh
| Company | Quality | Value | Shares |
|---|---|---|---|
 ALUMIS INC.$ALMS | 9.2#2,817 | $129.9M | 5,896,995 |
 CG Oncology, Inc.$CGON | 28.0#2,455 | $68.0M | 1,004,050 |
 Disc Medicine, Inc.$IRON | — | $23.9M | 374,069 |
 Hims & Hers Health, Inc.$HIMS | 50.9 | $15.3M | 738,151 |
 Eikon Therapeutics, Inc.$EIKN | — | $14.0M | 1,318,983 |
 Lyell Immunopharma, Inc.$LYEL | 3.6 | $9.6M | 477,078 |
 Pharvaris N.V.$PHVS | — | $5.5M | 194,125 |
 Nurix Therapeutics, Inc.$NRIX | 13.2 | $4.1M | 265,000 |
 Maze Therapeutics, Inc.$MAZE | 19.7 | $773.3K | 25,905 |
Unlock AI quality scores for every holding
32-signal composite ranking on each of Foresite Capital Management V, LLC's 9 positions.
Showing top 9 of 9 holdings.
Sector Allocation
Healthcare
$271.0M
Full Holdings — Foresite Capital Management V, LLC (Q1 2026)
All 9 disclosed positions from the latest Form 13F-HR, with quarter-over-quarter share changes and 13F Pro quality scores. Sourced from SEC EDGAR.
| # | Ticker | Company | Value | Weight | QoQ | Quality |
|---|---|---|---|---|---|---|
| 1 | $ALMS | ALUMIS INC. | $129.9M | 47.9% | +2% | 9.2 |
| 2 | $CGON | CG Oncology, Inc. | $68.0M | 25.1% | +0% | 28 |
| 3 | $IRON | Disc Medicine, Inc. | $23.9M | 8.8% | +25% | — |
| 4 | $HIMS | Hims & Hers Health, Inc. | $15.3M | 5.7% | +170% | 50.9 |
| 5 | $EIKN | Eikon Therapeutics, Inc. | $14.0M | 5.2% | NEW | — |
| 6 | $LYEL | Lyell Immunopharma, Inc. | $9.6M | 3.5% | +0% | 3.6 |
| 7 | $PHVS | Pharvaris N.V. | $5.5M | 2.0% | NEW | — |
| 8 | $NRIX | Nurix Therapeutics, Inc. | $4.1M | 1.5% | NEW | 13.2 |
| 9 | $MAZE | Maze Therapeutics, Inc. | $773,264 | 0.3% | -70% | 19.7 |
New Positions (3)
Exited Positions (1)
$NTRA Natera, Inc.Browse Top Institutional Investors
13F Pro tracks 8,700+ institutional investors filing 13F reports with the SEC.
to search all 8,700+ institutional filers.
Available Analysis
13F Pro tracks comprehensive institutional data for Foresite Capital Management V, LLC including:
Track Foresite Capital Management V, LLC's Full Portfolio
See every holding, quarter-over-quarter changes, sector allocation, and accumulation patterns for Foresite Capital Management V, LLC and 8,700+ other institutional investors.
Free tier includes full 13F search and fund profiles. Pro starts at $6.67/mo (billed annually).
AI-Powered Hedge Fund Analysis: Foresite Capital Management V, LLC
13F Pro is an AI hedge fund tracker and stock research platform. For Foresite Capital Management V, LLC (SEC CIK: 1792206), the platform ingests every quarterly Form 13F filing and applies AI-powered analysis on top — 10 specialized AI analysts (value, growth, momentum, macro, activist, and more) debate the fund's top positions and publish AI-generated analysis with cited SEC sources.
Every holding in Foresite Capital Management V, LLC's portfolio is scored on a 32-signal AI quality ranking (ROIC, FCF margin, revenue growth, institutional flow, earnings quality, shareholder dilution, and more). Track accumulation and distribution quarter over quarter, identify conviction positions, and see AI stock analysis for each position — alongside 8,700+ other institutional filers and 2,800+ AI-ranked companies.